DailyDoctor Archive Specialties Get app
Back to the 26 September 2026 edition

Research · 03 of 06

Adding posterior wall isolation to pulsed field PVI does not significantly cut AF recurrence

Do not routinely add posterior wall isolation to pulsed field PVI for persistent AF; this trial did not show a significant reduction in recurrence.

Design
Multicentre randomised superiority trial, blinded adjudication
Population
206 patients with symptomatic persistent AF
Primary outcome
Atrial tachyarrhythmia recurrence days 91–365 on implantable monitor
Effect
50.6% vs 60.6%; RR 0.75 (95% CI 0.51–1.09), P = 0.13

PIFPAF-PFA randomised 206 patients with symptomatic persistent atrial fibrillation at six Swiss centres to pulsed field pulmonary vein isolation (PVI) with or without posterior left atrial wall isolation. Every patient received an implantable loop recorder, so recurrence was measured continuously and adjudicated blind.

Atrial tachyarrhythmia of 30 seconds or longer recurred between days 91 and 365 in 50.6% with posterior wall isolation and 60.6% with PVI alone (RR 0.75, 95% CI 0.51–1.09; P = 0.13). Mean arrhythmia burden was lower (6.9% vs 11.0%), and recurrences lasting a day or longer were less frequent, but 22 of 29 secondary outcomes did not differ.

The primary result is neutral. The burden and longer-episode signals are interesting but come from a small trial with many secondary tests, and the authors call them hypothesis generating.

  • Pulmonary vein isolation alone remains a reasonable first ablation strategy in persistent AF.
  • Expect recurrence in about half to 60% of persistent AF patients within a year on continuous monitoring.
  • Counsel patients that 30-second recurrences are common and do not necessarily mean the ablation failed.
  • Ask about arrhythmia burden and symptoms, not just any recurrence, when judging ablation success.
  • Posterior wall isolation by pulsed field added two safety events in this trial; weigh it case by case.

Why it matters

It tempers the move to extend lesion sets just because pulsed field energy makes them easier.

Don't overread it

The secondary burden benefit comes from one of 29 end points in a 206-patient trial.

The statistics, in plain English

A rate ratio of 0.75 with a confidence interval of 0.51 to 1.09 crosses 1.0, so the trial could not exclude no effect. With 29 secondary outcomes, a few will look significant by chance; the burden difference (P = 0.04) is borderline and should be read as a lead, not a finding.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

heartfailurestructuralacsafibinterventionlipidology

Tomorrow morning, before your first patient

One edition a day for cardiology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free
Daily Doctor All 27 specialties, every morning. Free.
Get the app